QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
?Real-world data- trick or treat?
Data that’s not fit-for-purpose can be scary, but here’s the good news – Nordic data has many characteristics that allow it to be considered high-quality for a wide range of purposes. These include:
✔️ Complete population coverage for administrative (claims-type) data
✔️ Long patient follow-up of 20+ years
✔️ Wide set of variables that holistically characterise patients including SDOH
✔️ Deterministic, patient-level linkage between all datasets
✔️ Complete mortality data including date and cause […]
Need help choosing the right type of evidence review? The Quantify Research Evidence Review and Synthesis team is here to help!
In the pharmaceutical industry, evidence reviews are crucial for various activities such as HTA & reimbursement, regulatory submissions, RWE strategic planning, evidence gap identification, and GVD development.
Leverage the expertise of our Evidence Review & Synthesis team to determine the most appropriate review type, tailored to your priorities and use-cases.
Get in touch with our Head of the Evidence Review & Synthesis, Puneet Kaushik, (puneet.kaushik@quantifyresearch.com) […]
How can global pharma harness the power of Nordic RWE?
Check out the latest issue of PharmaTimes, where our CEO Kirk Geale explains how global pharmaceutical executives can harness the power of Nordic health data.
Nordic RWD are globally unique and practitioners should not miss the opportunities available in this region. This article provides an introduction to the data and spells out some exciting use cases.
Check out the feature here
Quantify co-authors IFPA report on Western Pacific Region’s progress towards WHO goals for psoriasis
How has the Western Pacific Region progressed towards the World Health Organization’s goals for psoriasis care? Find out in the IFPA’s (International Federation for Psoriasis Associations) recently published Index Report, co-authored by Quantify Research!
In the report, five key recommendations are presented to stakeholders:
1. Pursue reductions in psoriatic disease stigma
2. Reduce the stigma associated with mental health care from the perspectives of both patients and care providers
[…]